Transtornos e efeitos tóxicos relacionados com o cannabis

Referencias

1. Radwan MM, Chandra S, Gul S, El Sohly MA. Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules 2021; 26:2774.

2. National Conference of State Legislatures. State medical cannabis laws. November 8, 2023 (https://www.ncsl.org/ health/state-medical-cannabis-laws).

3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision. Washington, DC: American Psychiatric Association, 2022.

4. United Nations Office on Drugs and Crime. World drug report 2022 (https://www.unodc.org/ unodc/en/data-and-analysis/world-drug-report-2022.html).

5. Substance Abuse and Mental Health Services Administration. 2021 National survey on drug use and health: detailed tables. January 4, 2023 (https://www.samhsa.gov/data/report/2021-nsduh-detailed-tables).

6. Solmi M, Radua J, Olivola M, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry 2022; 27:281-95.

7. Sherman BJ, Baker NL, Schmarder KM, McRae-Clark AL, Gray KM. Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug Alcohol Depend 2021; 218:108383.

8. John WS, Zhu H, Mannelli P, Schwartz RP, Subramaniam GA, Wu L-T. Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. Drug Alcohol Depend 2018; 187:79-87.

9. Rhee TG, Rosenheck RA. Associations of current and remitted cannabis use disorder with health-related quality of life and employment among US adults. J Addict Med 2022; 16:286-94.

10. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 2018; 5:987-1012.

11. Drummer OH, Gerostamoulos D, Woodford NW. Cannabis as a cause of death: a review. Forensic Sci Int 2019;298: 298-306.

12. Weye N, Santomauro DF, Agerbo E, et al. Register-based metrics of years lived with disability associated with mental and substance use disorders: a register based cohort study in Denmark. Lancet Psychiatry 2021; 8:310-9.

13. Substance Abuse and Mental Health Services Administration. Preliminary findings from drug-related emergency department visits, 2021. May 31, 2022 (https://www.samhsa.gov/data/).

14. Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 2010; 29:318-30.

15. Kendler KS, Ohlsson H, Sundquist K, Sundquist J. Drug abuse-associated mortality across the lifespan: a population based longitudinal cohort and co-relative analysis. Soc Psychiatry Psychiatr Epidemiol 2017; 52:877-86.

16. Lu H-C, Mackie K. Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging 2021;6: 607-15.

17. Hu SS-J, Mackie K. Distribution of the endocannabinoid system in the central nervous system. In: Pertwee RG, ed. Endocannabinoids. New York: Springer Publishing, 2015:59-93.

18. Spindle TR, Kuwabara H, Eversole A, et al. Brain imaging of cannabinoid type I (CB 1) receptors in women with cannabis use disorder and male and female healthy controls. Addict Biol 2021;26(6): e13061.

19. Vitale RM, Iannotti FA, Amodeo P. The (poly)pharmacology of cannabidiol in neurological and neuropsychiatric disorders: molecular mechanisms and targets. Int J Mol Sci 2021; 22:4876.

20. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018; 84:2477-82.

21. Noble MJ, Hedberg K, Hendrickson RG. Acute cannabis toxicity. Clin Toxicol (Phila) 2019; 57:735-42.

22. Ramaekers JG, Mason NL, Kloft L, Theunissen EL. The why behind the high: determinants of neurocognition during acute cannabis exposure. Nat Rev Neurosci 2021; 22:439-54.

23. Ghasemiesfe M, Ravi D, Vali M, et al. Marijuana use, respiratory symptoms, and pulmonary function: a systematic review and meta-analysis. Ann Intern Med 2018; 169:106-15.

24. Chatkin JM, Zani-Silva L, Ferreira I, Zamel N. Cannabis-associated asthma and allergies. Clin Rev Allergy Immunol 2019; 56:196-206.

25. Harding BN, Austin TR, Floyd JS, Smith BM, Szklo M, Heckbert SR. Selfreported marijuana use and cardiac arrhythmias (from the Multiethnic Study of Atherosclerosis). Am J Cardiol 2022;177: 48-52.

26. Arkell TR, McCartney D, McGregor IS. Medical cannabis and driving. Aust J Gen Pract 2021; 50:357-62.

27. Wong KU, Baum CR. Acute cannabis toxicity. Pediatr Emerg Care 2019;35: 799-804.

28. Takakuwa KM, Schears RM. The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review. Int J Emerg Med 2021; 14:10.

29. Chartier C, Penouil F, Blanc-Brisset I, Pion C, Descatha A, Deguigne M. Pediatric cannabis poisonings in France: more and more frequent and severe. Clin Toxicol (Phila) 2021; 59:326-33.

30. Gorelick DA. Pharmacological treatment of cannabis-related disorders: a narrative review. Curr Pharm Des 2016;22: 6409-19.

31. Crippa JAS, Derenusson GN, Chagas MHN, et al. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J 2012; 9:7.

32. Crocker CE, Carter AJE, Emsley JG, Magee K, Atkinson P, Tibbo PG. When cannabis use goes wrong: mental health side effects of cannabis use that present to emergency services. Front Psychiatry 2021; 12:640222.

33. Petrowski K, Conrad R. Comparison of cortisol stress response in patients with panic disorder, cannabis-induced panic disorder, and healthy controls. Psychopathology 2019; 52:26-32.

34. Pearson NT, Berry JH. Cannabis and psychosis through the lens of DSM-5. Int J Environ Res Public Health 2019; 16:4149.

35. Rognli EB, Taipale H, Hjorthøj C, et al. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016. Psychol Med 2023; 53:5246-55.

36. Carvalho C, Vieira-Coelho MA. Cannabis induced psychosis: a systematic review on the role of genetic polymorphisms. Pharmacol Res 2022; 181:106258.

37. Fiorentini A, Cantù F, Crisanti C, Cereda G, Oldani L, Brambilla P. Substance induced psychoses: an updated literature review. Front Psychiatry 2021; 12:694863.

38. Velzeboer R, Malas A, Boerkoel P, et al. Cannabis dosing and administration for sleep: a systematic review. Sleep 2022; 45(11): zsac218.

39. Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction 2022; 117:2075-95.

40. Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. DSM-5 cannabis withdrawal syndrome: demographic and clinical correlates in U.S. adults. Drug Alcohol Depend 2019; 195:170-7.